ROBINS HARLAN S sold $8.5M of ADPT

ROBINS HARLAN S (Chief Scientific Officer) sold 386,240 shares of Adaptive Biotechnologies Corp (ADPT) at an average of $22.01 ($21.74–$22.45, $8.50M total) across 2 trades on 2026-07-02 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · ROBINS HARLAN S
Published Jul 7, 2026, 10:52 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 7, 2026, 10:58 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ADPT
Neutral
high confidence
Mentioned
$ADPT
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ADPTNeutralLow
01

Why it matters

The newest fact is the disclosed sale size, price range ($21.7400–$22.4500), and that it was executed under a pre-arranged 10b5-1 plan.

02

Market read

Traders may monitor for follow-on insider activity, but this specific disclosure alone is unlikely to drive a fundamental repricing.

03

What to watch

The filing does not state whether other insiders sold/bought around the same time, nor does it provide post-sale performance context.

Relevance 5/10Novelty 3/10Timing: Filed July 7 after the July 2 insider sale execution.

Background

The article is an SEC Form 4 insider transaction disclosure for Adaptive Biotechnologies (ADPT).

Company-level read

Ticker impact

$ADPTNeutralHigh confidence
Context

Form 4 shows Chief Scientific Officer Robins Harlan S sold 386,240 ADPT shares for about $8.5M under a 10b5-1 plan.

Expected impact

Likely limited/short-lived impact; any move would be sentiment-driven rather than catalyst-driven.

Evidence & confidence

The filing is a routine 10b5-1 sale disclosure with no accompanying guidance, deal, or regulatory/clinical update in the text.

Market effects

Minimal; no sector-wide signal is provided beyond a single-company insider transaction.

None indicated.

None indicated.

Counterpoint

Because it’s a 10b5-1 plan, the sale may be largely mechanical and not a bearish read-through; traders may discount it.

Key entities

  • Adaptive Biotechnologies Corp

    Subject of the Form 4 insider sale disclosure.

  • Robins Harlan S

    Chief Scientific Officer who sold 386,240 shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ADPTHigh

Adaptive (ADPT) Q3 2026 Earnings Call Transcript

Adaptive (ADPT) raised its 2026 MRD revenue guidance due to strong clinical volumes and pharma revenue. Q3 saw 46% YOY growth in clinical testing volume, with 41% growth in clinical revenue. The company earned a milestone payment from Pfizer and is advancing its immune medicine separation process. Blood-based testing and community adoption of clonoSEQ increased significantly. U.S. ASP was $1,380 in Q3, with coverage gains in DLBCL and MCL.

$ADPTHigh

Adaptive Biotechnologies Corp (ADPT) Q3 2026 Earnings Call Highlights: First Profitable

Adaptive Biotechnologies (ADPT) reported Q3 2026 revenue of $83.9M, up 39% YoY, with GAAP net income of $2.8M. US ASP was $1,380, flat sequentially. The company expects no GAAP net income for Q4 or the full year. Challenges include Medicare payment structures and CMS rate uncertainties. Management remains confident in long-term pricing strategy and growth, citing favorable guidelines and market expansion.

$ADPTMedAI 8/10

Adaptive Biotechnologies Q3 Earnings Call Highlights

Adaptive Biotechnologies (ADPT) reported Q3 2026 revenue of $83.9M, up 39% YoY, with GAAP net income of $2.8M. The company raised its full-year MRD revenue outlook to $276M-$286M. Clinical testing volume increased 46% YoY, and clonoSEQ tests grew 10% sequentially. Adaptive expects 42% clinical volume growth for the year and is pursuing Medicare reimbursement updates.